Evidence map›Paper›PMID 39372093›Full record

ArticleBioelectricity2024

The CellFX Percutaneous Electrode System for Nanosecond Pulsed Field Ablation.

Richard Nuccitelli, Jeffrey Litt, Kevin Moss, Dale Hinman, Ilya Getsin, Darrin Uecker, Bill Stoffregen, William A Knape

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Bioelectricity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Richard NuccitelliPulse Biosciences, Inc., Hayward, California, USA.ORCID https://orcid.org/0000-0002-1089-3194
Jeffrey LittPulse Biosciences, Inc., Hayward, California, USA.
Kevin MossPulse Biosciences, Inc., Hayward, California, USA.
Dale HinmanPulse Biosciences, Inc., Hayward, California, USA.
Ilya GetsinPulse Biosciences, Inc., Hayward, California, USA.
Darrin UeckerPulse Biosciences, Inc., Hayward, California, USA.
Bill StoffregenNorthstar Preclinical and Pathology Services, Lake Elmo, Minnesota, USA.
William A KnapePulse Biosciences, Inc., Hayward, California, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The purpose of this study was to demonstrate the safety and performance of the CellFX Percutaneous Electrode for delivering nanosecond pulsed field ablation (nsPFA) energy to soft tissues. Three different porcine tissue types were treated, namely, liver, kidney, and skeletal muscle, at treatment levels of three times greater than clinical treatment levels. The histological characteristics of the ablation zone for each of these tissues compared with that of radiofrequency (RF) ablation on day 0 and 2 days post-treatment. Ablation zone dimensions were measured during gross necropsy after tetrazolium chloride staining and compared between the nsPFA and RF groups at 2 days post-ablation. The CellFX system successfully achieved ablation and necrosis of all treatment sites in all target tissues. No evidence of thermal effects or collagen degeneration was found at any of the nsPFA treatment sites. Overall systemic tolerability was evidenced by the absence of clinically significant changes in urinalysis and serum chemistry before and after treatments.

Indexed as

ablationapoptosisCellFXnanosecond electric pulsesNanosecond pulsed field ablationnsPFApercutaneous electroderegulated cell death

Identifiers

PMID39372093
PMCPMC11447478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.